Consult the medical resource doctors trust
UpToDate is one of the most respected medical information resources in the world, used by over 360,000 doctors and thousands of patients to find answers to medical questions.
Related articles
![]() | Preview Available (subscription required for full access) |
















| AuthorMorton F Arnsdorf, MD, MACC | Section EditorBradley P Knight, MD, FACC | Deputy EditorsLeah K Moynihan, RNC, MSNGordon M Saperia, MD, FACC |
Contents of this article
Atrial fibrillation (also called AF or a-fib) is an abnormal rhythm of the heart. It is relatively common, affecting 2.3 million adults in the United States. Most people who develop atrial fibrillation are over 65 years of age. Atrial fibrillation is more frequent in men than women, and in whites than blacks.
There are two forms of this abnormal heart rhythm:
The purpose of this review is to describe the symptoms of atrial fibrillation, its risks, and to review current treatments.
In atrial fibrillation, part of the heart does not work correctly because of abnormal electrical activity. This means that only a small amount of blood is pumped out. The blood that remains in the atria becomes "sluggish" or static, which allows blood clots to form (see 'Risk of stroke' below.
Atrial fibrillation increases in frequency with aging and typically occurs in people who have underlying heart disease. Almost any heart disease can increase the risk of this abnormal rhythm, but the most common causes are:
Atrial fibrillation can also be induced by external events. These include:
Some people with atrial fibrillation have no apparent cause. When this occurs in people under age 60 to 65, it is called lone atrial fibrillation. The cause is not well understood, but the risk of blood clots is much lower in this group.
Some people have no symptoms of AF while others have debilitating shortness of breath. Mild symptoms include:
As the ventricles beat more rapidly or irregularly, symptoms may be more severe and include:
Chest discomfort generally results from inadequate blood flow to meet the needs of the heart (called angina); this can be due to an increase in the heart's need for oxygen and/or a decrease in the heart's supply of blood and oxygen. In some cases, chest pain is due to the rapid heart rate itself or perhaps due to stretching of the heart's chambers. Chest discomfort can also result from worsening heart failure.
Risk of stroke — A serious complication associated with atrial fibrillation is stroke, which can lead to permanent brain damage. A stroke can occur if a blood clot forms in the left atrium because of sluggish blood flow and a piece of the clot (called an embolus) breaks off. The embolus enters the blood circulation and can block a small blood vessel. If this happens in the brain, a stroke can occur. The embolus may also travel to the eye, kidneys, spine, or important arteries of the arms or legs. (See "Patient information: Stroke symptoms and diagnosis".)
Like atrial fibrillation, the risk of stroke increases with age. Without preventive treatment (eg, blood thinners), stroke occurs in approximately 1.3 percent of people with AF who are 50 to 59 years and increases gradually to 5 percent each year for people 80 to 89 years.
Taking a blood thinner (usually warfarin [Coumadin®]) lowers the risk of stroke (see 'Treatment to prevent blood clots' below.
Atrial fibrillation is diagnosed with an electrocardiogram (ECG or EKG), which records the heart's electrical activity. Other tests such as an echocardiogram (ultrasound), may be performed to look for heart failure or heart valve problems, while lung function tests are sometimes used to look for underlying lung disease.
Electrical cardioversion — Electrical cardioversion involves the use of an electrical shock from a cardioverter, delivered by paddles placed on the chest, to "reset" the heart rhythm. Urgent cardioversion is usually performed if AF is interfering with heart's ability to supply blood and oxygen to vital organs. (See "Patient information: Cardioversion".)
Some people with newly diagnosed AF can undergo electrical or medical cardioversion (using an antiarrhythmic drug) immediately. However, due to the risk of stroke from blood clots lodged in the left atrium, many people are advised to delay cardioversion until starting treatment with a blood thinner. This medication, (usually warfarin [Coumadin®]) is given for three to four weeks, which allows 85 percent of preexisting blood clots in the left atrium to resolve.
Transesophageal echocardiogram — Use of procedure called transesophageal echocardiogram (TEE) is an alternative to delaying cardioversion while starting a blood thinner. TEE uses a small ultrasound device that is swallowed. The device allows the physician to see the left atria, looking for evidence of clots or slowed blood flow. If the atria appear to be without clots or slowed blood flow, cardioversion can be performed safely without warfarin pretreatment. Although there is still a risk that cardioversion may dislodge a clot that was not seen on the TEE, the risk is quite small.
Long term treatment — For people with intermittent or chronic atrial fibrillation, there are two long-term treatment options: rhythm control and rate control.
Rhythm control — Rhythm control refers to electrical or medical cardioversion followed by an antiarrhythmic drug to lower the risk of recurrent AF. After successful conversion to normal sinus rhythm, only 20 to 30 percent of people are in sinus rhythm after one year. This can be increased to between 40 and 80 percent by adding an antiarrhythmic drug.
The advantages to rhythm control include improved cardiac function and, for some people, reduced symptoms. Selected people who maintain a normal rhythm are allowed to stop blood thinning medications. However, rhythm control is more likely to reduce the frequency of AF than eliminate it entirely. Thus, most people treated with antiarrhythmic medications should continue blood thinners indefinitely.
The disadvantages of rhythm control are the high rate of recurrent AF and side effects associated with antiarrhythmic drugs, including the development of new abnormal heart rhythms.
Rate control — People who are treated with rate control continue to have AF. However, the person uses a medication (a beta blocker, a calcium channel blocker, or digoxin) to slow conduction through the AV node, thereby keeping the ventricular rate in the normal range. People who use this treatment require treatment with a blood thinner since there is a risk of blood clot formation and possible stroke. (See 'Treatment to prevent blood clots' below.)
There are two major disadvantages with the rate control strategy: it is sometimes difficult to adequately control the rate and relieve symptoms; and chronic use of blood thinning medications carries a risk of bleeding.
A 2003 guideline from two major medical societies recommends rate control, along with a treatment to prevent blood clots, for the majority of patients. You should discuss the risks and benefits of each type of treatment with your doctor or nurse.
Nonpharmacologic treatments — There are alternate ways to achieve rhythm or rate control, including radiofrequency catheter ablation, use of a pacemaker or implantable atrial defibrillator, and several surgical treatments. (See "Patient information: Pacemakers" and "Patient information: Implantable cardioverter-defibrillators".)
Radiofrequency ablation — Radiofrequency ablation is a procedure that can sometimes cure atrial fibrillation. The technique, however, is still evolving, and there is a small but real risk of serious complications, even with an experienced physician. (See "Patient information: Radiofrequency catheter ablation".)
Increasingly, this therapy is being considered an initial option in young people who have symptoms of a-fib who do not wish to take long-term medications. It is also being used increasingly in patients who are having recurrent atrial fibrillation despite using one or more antiarrhythmic drug. (See "Radiofrequency catheter ablation to prevent recurrent atrial fibrillation".)
Surgical procedures — Surgical procedures, including the maze procedure and the corridor operation, may be considered in some people with AF, especially those who must undergo open-heart surgery for other reasons. (See "Surgical approaches to prevent recurrent atrial fibrillation".)
TREATMENT TO PREVENT BLOOD CLOTS
People with atrial fibrillation have an increased risk of stroke as a result of blood clots that can form in the heart. As a result, most people are advised to use a treatment to reduce the risk of developing blood clots. The most commonly used treatments include warfarin (Coumadin®) and aspirin alone. Dabigatran and clopidogrel (Plavix®) may also be used.
Warfarin — Taking warfarin can reduce the risk of having a stroke by approximately 50 to 70 percent. (See "Patient information: Warfarin (Coumadin®)".)
The major problem with warfarin therapy is that it increases the risk of bleeding. The most serious type of bleeding is bleeding into the brain. However, the benefit of preventing strokes is greater than the small risk of bleeding into the brain in most cases. If you take warfarin, you will need careful monitoring with periodic blood tests to be sure you are taking the right dose of warfarin.
Aspirin — Warfarin is the most effective treatment for preventing blood clots in patients at high-risk of stroke. However, treatment with aspirin is a reasonable option in certain people.
Your healthcare provider is the best source of information for questions and concerns related to your medical problem. Because no two people are exactly alike and recommendations can vary from one person to another, it is important to seek guidance from a provider who is familiar with your individual situation.
This discussion will be updated as needed every four months on our web site (www.uptodate.com/patients). Additional topics as well as selected discussions written for healthcare professionals are also available for those who would like more detailed information.
Some of the most pertinent include:
Patient Level Information:
Patient information: A guide to atrial fibrillation
Patient information: Mitral regurgitation
Patient information: Hyperthyroidism
Patient information: Sleep apnea in adults
Patient information: Stroke symptoms and diagnosis
Patient information: Cardioversion
Patient information: Pacemakers
Patient information: Implantable cardioverter-defibrillators
Patient information: Radiofrequency catheter ablation
Patient information: Warfarin (Coumadin®)
Professional Level Information:
Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations
Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation
Antithrombotic therapy to prevent embolization in nonvalvular atrial fibrillation
Causes of atrial fibrillation
Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy
Control of ventricular rate in atrial fibrillation: Pharmacologic therapy
Implantable atrial defibrillators for the treatment of atrial fibrillation
Lone and low-risk atrial fibrillation
Overview of the evaluation and management of atrial fibrillation
Paroxysmal atrial fibrillation
Radiofrequency catheter ablation to prevent recurrent atrial fibrillation
Restoration of sinus rhythm in atrial fibrillation: Recommendations
Restoration of sinus rhythm in atrial fibrillation: Therapeutic options
Rhythm control versus rate control in atrial fibrillation
Role of echocardiography in atrial fibrillation
Surgical approaches to prevent recurrent atrial fibrillation
Patient information: A guide to atrial fibrillation
A number of web sites have information about medical problems and treatments, although it can be difficult to know which sites are reputable. Information provided by the National Institutes of Health, national medical societies and some other well-established organizations are often reliable sources of information, although the frequency with which they are updated is variable.
(www.nlm.nih.gov/medlineplus/healthtopics.html)
(www.yourdiseaserisk.harvard.edu/)
Includes a calculator for estimating the risk of stroke
[1-8]
| References |
Top
|
UpToDate performs a continuous review of over 430 journals and other resources. Updates are added as important new information is published. The literature review for version 17.3 is current through September 2009; this topic was last changed on October 13, 2009. The next version of UpToDate (18.1) will be released in March 2010.
![]() |
Please wait |